OGIVRI

Approval Id: be60b306893af090
Drug Approval Canada Name: OGIVRI
Product Name: OGIVRI
Status: Marketed
Status Date: 2024-02-15
Original Market Date: 2019-06-06
Din: 02474433
Drug Class: Human
Dosage Form: Powder For Solution
Route Of Administration: Intravenous
Schedule: Prescription , Schedule D
Ahfs: 10:00.00
Atc Original: L01FD01 TRASTUZUMAB
Atc Name: l 01 fd 01
Aig Number: 0238103001
Company Name: Biosimilar Collaborations Ireland Ltd.
Company Address: UNIT 35/36, Grange Parade, Baldoyle Industrial Estate, Dublin 13, Dublin, --, Ireland, D13R20R
Company Detail Path: /organization/biosimilar-collaborations-ireland-ltd

TRASTUZUMAB

440 MG / VIAL

WATER

20 ML / VIAL

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

be60b306893af090

Type

Standard